Starting with BNY Mellon Natural Resources A (DNLAX) should not be a possibility at this time. DNLAX bears a Zacks Mutual Fund Rank of 4 (Sell), which is based on various forecasting factors like size ...

Abstract: Split learning (SL) aims to protect user data privacy by distributing deep models between the client-server and keeping private data locally. In SL training with multiple clients, the local ...

Wisp, the largest pure play women's telehealth company in the U.S., today announced the expansion of its weight care vertical, delivering the most affordable all-in, name-brand GLP-1s directly to the ...

Stephen Moore, who formerly wrote on the economy and public policy for The Wall Street Journal, is a distinguished visiting fellow for the Project for Economic Growth at The Heritage Foundation. He ...

On Tuesday, the Bureau of Labor Statistics (BLS) published a revision of its latest job numbers, a report that shows just how far off its estimates of overall employment were from reality. The latest ...

Sept 7 (Reuters) - Standard Chartered expects the U.S. Federal Reserve to cut interest rates by 50 basis points at its policy meeting this month, double its earlier projection of a 25-bp reduction, ...

bDepartment of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China cDepartment of Clinical Epidemiology and Evidence-Based Medicine, ...

Viking Therapeutics (NASDAQ:VKTX) lost ~38% in the premarket on Tuesday after announcing that its oral tablet formulation of its GLP-1/GIP dual receptor agonist VK2735 caused up to 12.2% of weight ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. The natural gas pipeline network has a complex topology with variable flow directions, ...

Introduction: Very-low-birthweight (VLBW) infants on pasteurized donor human milk (PDHM) have poorer growth compared to infants on fortified mother's milk, suggesting that standard fortification ...

Eli Lilly & Co. tumbled as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...